Psychedelic Archives

Video StaffNovember 27, 2023

Green Market Report had a chance to sit down with Rock Feilding-Mellen to discuss the recent capital raise by Beckley Waves. The company is focused on building its academy to help train therapists in psychedelic drug treatments. The company believes that when MDMA is approved for MAPS, there will be a huge need for these […]

Debra BorchardtNovember 21, 2023

The initiative seeks to legalize the use of psychedelics in licensed facilities.

Debra BorchardtNovember 20, 2023

A reduction in publicly-traded psychedelic companies is expected.

Debra BorchardtNovember 15, 2023

After the markets closed on Tuesday, Cybin Inc. (NYSE: CYBN) (NEO: CYBN) reported unaudited financial results for its second quarter ended Sept. 30. Cybin reported a net loss of C$11.9 million for the quarter versus last year’s net loss of C$10 million. At present, Cybin’s operations do not generate cash flows and at the end of […]

Debra BorchardtNovember 15, 2023

Even if Enveric receives regulatory approval for its compounds, it would still need funds for manufacturing.

Debra BorchardtNovember 15, 2023

Atai says it is has enough funds to last until the first half of 2026

Debra BorchardtOctober 11, 2023

Atai Life Sciences AG (Nasdaq: ATAI) clearly believes in the medical technology from IntelGenx Technologies Corp. (OTC: IGXT) as the company has leaned into its investment. In August, IntelGenX announced that it closed on a private placement from Atai that brought the company roughly $3 million and now that could be increased. Following this transaction, […]

Debra BorchardtSeptember 1, 2023

Functional mushroom company Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) following the company’s release of its unaudited financials for the quarter ending May 2023, announced that it has closed a second tranche of its previously announced non-brokered private placement effective August 31, 2023, for gross proceeds of $4.5 million. The company said it worked with Gotham […]

Debra BorchardtAugust 10, 2023

Atai Life Sciences (NASDAQ: ATAI) reported its second quarter 2023 financial results and provided corporate updates. At this time Atai has no revenue to report. Atai did report a net loss of $33.1 million for the quarter (including non-cash share-based compensation expense of $8.8 million). This was slightly lower than last year’s net loss of […]

Debra BorchardtJune 8, 2023